Heron Therapeutics, Inc. NASDAQ:HRTX

Heron Therapeutics stock price today

$1.28
-0.27
-17.42%
Financial Health
0
1
2
3
4
5
6
7
8
9

Heron Therapeutics stock price monthly change

-52.16%
month

Heron Therapeutics stock price quarterly change

-52.16%
quarter

Heron Therapeutics stock price yearly change

-7.19%
year

Heron Therapeutics key metrics

Market Cap
236.50M
Enterprise value
439.34M
P/E
-1.36
EV/Sales
2.76
EV/EBITDA
-1.48
Price/Sales
1.87
Price/Book
21.90
PEG ratio
-0.05
EPS
-0.61
Revenue
132.09M
EBITDA
-79.48M
Income
-80.95M
Revenue Q/Q
17.06%
Revenue Y/Y
16.04%
Profit margin
-190.4%
Oper. margin
-180.83%
Gross margin
48.09%
EBIT margin
-180.83%
EBITDA margin
-60.17%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Heron Therapeutics stock price history

Heron Therapeutics stock forecast

Heron Therapeutics financial statements

Heron Therapeutics, Inc. (NASDAQ:HRTX): Profit margin
Jun 2023 31.76M -42.05M -132.42%
Sep 2023 31.43M -25.00M -79.56%
Dec 2023 34.23M -10.72M -31.33%
Mar 2024 34.67M -3.16M -9.11%
Heron Therapeutics, Inc. (NASDAQ:HRTX): Analyst Estimates
2025 177.92M 1.41M 0.8%
2026 216.53M 39.5M 18.24%
2027 244.4M 45.58M 18.65%
2028 288.76M 62.85M 21.77%
  • Analysts Price target

  • Financials & Ratios estimates

Heron Therapeutics, Inc. (NASDAQ:HRTX): Debt to assets
Jun 2023 201224000 240.50M 119.52%
Sep 2023 229199000 256.98M 112.12%
Dec 2023 222506000 256.47M 115.27%
Mar 2024 217887000 251.65M 115.5%
Heron Therapeutics, Inc. (NASDAQ:HRTX): Cash Flow
Jun 2023 -27.16M 13.21M 319K
Sep 2023 -9.17M -23.22M 53.79M
Dec 2023 2.45M -8.83M 199K
Mar 2024 -9.51M 1.27M 11K

Heron Therapeutics alternative data

Heron Therapeutics, Inc. (NASDAQ:HRTX): Employee count
Aug 2023 203
Sep 2023 203
Oct 2023 203
Nov 2023 203
Dec 2023 203
Jan 2024 203
Feb 2024 203
Mar 2024 126
Apr 2024 126
May 2024 126
Jun 2024 126
Jul 2024 126

Heron Therapeutics other data

100.00% 0.00%
of HRTX is owned by hedge funds
118.16M -289.73K
shares is hold by hedge funds

Heron Therapeutics, Inc. (NASDAQ:HRTX): Insider trades (number of shares)
Period Buy Sel
Jul 2023 3649635 0
Nov 2023 310000 0
Transaction Date Insider Security Shares Price per share Total value Source
Option
FORBES WILLIAM P officer: EVP, Chief Development..
Common Stock 12,500 N/A N/A
Option
FORBES WILLIAM P officer: EVP, Chief Development..
Restricted Stock Units 12,500 N/A N/A
Option
DUARTE IRA officer: EVP, Chief Financial O..
Common Stock 3,874 N/A N/A
Option
DUARTE IRA officer: EVP, Chief Financial O..
Restricted Stock Units 3,874 N/A N/A
Option
FORBES WILLIAM P officer: EVP, Chief Development..
Common Stock 3,874 N/A N/A
Option
FORBES WILLIAM P officer: EVP, Chief Development..
Restricted Stock Units 3,874 N/A N/A
Option
COLLARD CRAIG A director, officer: Chief Execut..
Common Stock 13,797 N/A N/A
Option
COLLARD CRAIG A director, officer: Chief Execut..
Common Stock 62,500 N/A N/A
Option
COLLARD CRAIG A director, officer: Chief Execut..
Restricted Stock Units 62,500 N/A N/A
Option
COLLARD CRAIG A director, officer: Chief Execut..
Restricted Stock Units 13,797 N/A N/A
Wednesday, 4 December 2024
seekingalpha.com
Tuesday, 3 December 2024
prnewswire.com
Tuesday, 12 November 2024
seekingalpha.com
zacks.com
zacks.com
prnewswire.com
Thursday, 7 November 2024
zacks.com
Monday, 4 November 2024
prnewswire.com
Tuesday, 29 October 2024
prnewswire.com
Thursday, 10 October 2024
prnewswire.com
Wednesday, 25 September 2024
prnewswire.com
Tuesday, 3 September 2024
prnewswire.com
Tuesday, 6 August 2024
zacks.com
zacks.com
prnewswire.com
Tuesday, 30 July 2024
prnewswire.com
Monday, 15 July 2024
prnewswire.com
Thursday, 11 July 2024
zacks.com
zacks.com
Tuesday, 2 July 2024
prnewswire.com
Wednesday, 29 May 2024
prnewswire.com
Friday, 24 May 2024
zacks.com
Tuesday, 21 May 2024
zacks.com
Monday, 20 May 2024
https://www.defenseworld.net
Tuesday, 7 May 2024
seekingalpha.com
Zacks Investment Research
Zacks Investment Research
Tuesday, 12 March 2024
Seeking Alpha
Zacks Investment Research
Thursday, 7 March 2024
Zacks Investment Research
  • What's the price of Heron Therapeutics stock today?

    One share of Heron Therapeutics stock can currently be purchased for approximately $1.28.

  • When is Heron Therapeutics's next earnings date?

    Unfortunately, Heron Therapeutics's (HRTX) next earnings date is currently unknown.

  • Does Heron Therapeutics pay dividends?

    No, Heron Therapeutics does not pay dividends.

  • How much money does Heron Therapeutics make?

    Heron Therapeutics has a market capitalization of 236.50M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 17.99% to 127.04M US dollars.

  • What is Heron Therapeutics's stock symbol?

    Heron Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HRTX".

  • What is Heron Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Heron Therapeutics?

    Shares of Heron Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Heron Therapeutics's key executives?

    Heron Therapeutics's management team includes the following people:

    • Dr. Barry D. Quart Chairman & Chief Executive Officer(age: 68, pay: $1,060,000)
    • Ms. Kimberly J. Manhard Executive Vice President of Drug Devel. & Director(age: 65, pay: $727,690)
    • Mr. John W. Poyhonen Pres & Chief Commercial Officer(age: 65, pay: $720,450)
    • Mr. David L. Szekeres Executive Vice President & Chief Operating Officer(age: 51, pay: $647,120)
    • Ms. Lisa Peraza Vice President & Chief Accounting Officer(age: 48, pay: $449,060)
  • How many employees does Heron Therapeutics have?

    As Jul 2024, Heron Therapeutics employs 126 workers.

  • When Heron Therapeutics went public?

    Heron Therapeutics, Inc. is publicly traded company for more then 38 years since IPO on 26 Aug 1987.

  • What is Heron Therapeutics's official website?

    The official website for Heron Therapeutics is herontx.com.

  • Where are Heron Therapeutics's headquarters?

    Heron Therapeutics is headquartered at 4242 Campus Point Court, San Diego, CA.

  • How can i contact Heron Therapeutics?

    Heron Therapeutics's mailing address is 4242 Campus Point Court, San Diego, CA and company can be reached via phone at 858 251 4400.

Heron Therapeutics company profile:

Heron Therapeutics, Inc.

herontx.com
Exchange:

NASDAQ

Full time employees:

126

Industry:

Biotechnology

Sector:

Healthcare

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

4242 Campus Point Court
San Diego, CA 92121

CIK: 0000818033
ISIN: US4277461020
CUSIP: 427746102